Replies to post #94994 on Biotech Values

[ghmm]

BMRN:

I am very curious to see what their end-point will be. I would like it to be Keratan sulfate but I don't think the FDA would go for that as the primary end point :-). They said they have over 600 patients identified already! I would want to be very cautious since I lost a lot of faith in PEG-PAL being a blockbuster. If they succeed the treatment will have an incredible sales ramp given the 300-400k annual price (maybe even more I think some of the other ERT's are a bit higher).